Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

or. Oral ulceration is a common side effect of Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is recommended when co-administered with a strong CYP3A4 inducer.  Live vaccinations and close contact with those who have received live vaccines should be avoided by patients taking Afinitor. Afinitor should not be used in patients with severe hepatic impairment. Afinitor may cause fetal harm in pregnant women.

The most common adverse reactions, irrespective of causality (incidence greater than or equal to 30%), were stomatitis (44%), infections (37%), asthenia (33%), fatigue (31%), cough (30%) and diarrhea (30%). The most common grade 3/4 adverse reactions, irrespective of causality (incidence greater than or equal to 3%), were infections (9%), dyspnea (8%), fatigue (5%), stomatitis (4%), dehydration (4%), pneumonitis (4%), abdominal pain (3%) and asthenia (3%). The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia (92%), hypercholesterolemia (77%), hypertriglyceridemia (73%), hyperglycemia (57%), lymphopenia (51%) and increased creatinine (50%). The most common grade 3/4 laboratory abnormalities (incidence greater than or equal to 3%) were lymphopenia (18%), hyperglycemia (16%), anemia (13%), hypophosphatemia (6%) and hypercholesterolemia (4%). Deaths due to acute respiratory failure (0.7%), infection (0.7%) and acute renal failure (0.4%) were observed in patients receiving Afinitor.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "to be submitted," "planned," "can," "potential," "will," "goal," or similar expressions, or by expres
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... For Pfizer, a key success factor in bringing ... the condition that the drug was designed to treat. ... shift the nomenclature for the condition from "impotence" (with ... dysfunction" (more clinical-sounding) to "ED" (casual and conversationally appropriate). ...
... At MEDRAD, Inc., community outreach is a celebrated ... Day of Caring, a company-sponsored event where employees ... volunteering in their communities. (Logo: ... 1000 MEDRAD employees will participate in the event ...
Cached Medicine Technology:Using Internal Communications to Help Build a Credible External Message Regarding New Pharmaceutical Products 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 2MEDRAD Employees Demonstrate Longstanding Commitment to Community 3
(Date:7/10/2014)... 2014 CBPartners, a global leader in ... a new website. The redesigned site boasts improved ... to the firm’s thought pieces, blog posts, and conference ... to showcase our insights, capabilities, and to provide timely ... Executive Officer, Cyrus Chowdhury. “An enhanced online presence ...
(Date:7/10/2014)... Port Washington, New York (PRWEB) July 10, 2014 ... law firm dedicated to protecting the rights of ... a couple has brought a lawsuit over allegations ... through her body by a power morcellator used ... lawsuit has been filed against Richard Wolf Medical ...
(Date:7/10/2014)... not nurture, may play the bigger role in the ... "As is the case in humans, genes matter ... William Hopkins of the Yerkes National Primate Research Center ... journal Current Biology . The findings might ... humans, Hopkins, team said. According to the researchers, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... the hot flashes that often accompany menopause, new research suggests. ... percent of menopausal women, said Dr. Taraneh Shirazian, an assistant ... Icahn School of Medicine at Mount Sinai Hospital in New ... 10 hot flashes a day, and she added that hot ...
(Date:7/10/2014)... 2014In response to today,s announcement that the "Mississippi Baby," ... now been found to have detectable levels of the ... disappointment in this setback but remains hopeful that the ... remain undetectable for more than two years will continue ... ultimately develop a cure. , "Although we had ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... Serena Gordon HealthDay Reporter , SUNDAY, May 20 (HealthDay ... of adverse health problems, such as high blood pressure and heart ... cancer, the sleep disorder may raise their risk of dying from ... who have 30 or more episodes of low or no oxygen ...
... , MONDAY, May 21 (HealthDay News) -- Shortness of ... chronic obstructive pulmonary disease (COPD), a new, small study ... can inhibit healthy sex lives and is more common ... is a term used to describe certain lung conditions ...
... Spanish . Flexible sigmoidoscopy, a screening test ... side effects than colonoscopy, is effective in reducing the rates ... to research sponsored by the National Cancer Institute, part of ... spanned almost 20 years, researchers found that overall colorectal cancer ...
... the UK, have just launched a major new trial investigating ... heart failure (CHF)., Since home oxygen therapy (HOT) can be ... required to offer some clear guidance about whether HOT should ... 669,000 people in the UK aged over 45 have the ...
... From Finland to Italy and from Spain to Lithuania, thirteen ... three-year Hialine study. The coordinator was Professor Dr Jeroen Buters ... Allergy & Environment (ZAUM). The mission was to study the ... pollen (germ cells) of birch trees, grass and olive plants. ...
... NY, May 21, 2012Currently more than 10% of preschoolers ... target pregnancy, infancy, and toddlers are urgently needed to ... proposed in an article in Childhood Obesity , ... The article is available free online ahead of print ...
Cached Medicine News:Health News:Sleep Apnea Linked to Higher Cancer Death Risk 2Health News:Sleep Apnea Linked to Higher Cancer Death Risk 3Health News:COPD Can Put a Damper on Sex Life 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 3Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 4Health News:Should oxygen be used for patients with chronic heart failure? 2Health News:Some pollens are much more aggressive than others 2Health News:A systems approach to preventing obesity in early life 2
Inquire...
Inquire...
... Before TOPscan Dispensers used to only have two ... process the completed job at a wholesale lab, ... The alternative was to finish the order in ... additional offices required another edger, lens inventory, more ...
Inquire...
Medicine Products: